Mayo Clinic HeartShare Clinical Center

梅奥诊所 HeartShare 临床中心

基本信息

  • 批准号:
    10679096
  • 负责人:
  • 金额:
    $ 28.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-10 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT This is Mayo Clinic’s application to participate in the NIH HeartShare Research Consortium as a HeartShare Clinical Center (CC). Our goal is to collaborate with the other HeartShare Investigators to elucidate the pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) and discover novel diagnostic and therapeutic approaches. Multiple pathophysiologic processes may ultimately lead to different HFpEF phenotypes, though the specific mechanisms remain largely undefined. It is also not known whether standard clinical information can identify patients with different mechanistic etiologies, which is necessary to provide targeted therapies in clinical trials and eventually in clinical practice. Our proposal outlines four specific aims. In Specific Aim 1: We document that Mayo Clinic has the resources and the Mayo HeartShare Team has the expertise and track record of productivity in HFpEF and relevant related diseases, clinical research, patient recruitment and retention, data science, and collaborative team science to help drive the success of HeartShare Network. In Specific Aim 2: We propose a broad mechanistic phenotyping protocol providing quantitative variables reflective of senescence, systemic disease processes, and multi-organ integrity (L2 data), which are used as input variables in unsupervised machine learning (ML) models. We hypothesize that this approach will allow identification of unique HFpEF pathophysiologic phenogroups (clusters). We also propose invasive hemodynamic signatures, trans-cardiac gradients of circulating biomarkers and myocardial, adipose and skeletal muscle tissue characterization (L3 data) be obtained in a subset within each HFpEF pathophysiologic phenogroup. We hypothesize these L3 data will enhance identification of targeted therapeutic strategies. Lastly, we outline supervised ML using EHR data to develop automatable algorithms to accurately identify the HeartShare HFpEF pathophysiological phenogroups derived using L2 data. We hypothesize that if successful, this approach will enhance translation of HeartShare findings by allowing automated identification of patients in the different HFpEF phenogroups for enrollment in clinical trials of agents targeting their specific pathophysiology. In Specific Aim 3: We propose that use of circulating proteins alone (n=5000; defined by the SOMAScanTM Aptamer based platform) as input variables for unsupervised ML models will identify unique HFpEF pathophysiologic phenotypes (clusters). In Specific Aim 4: We outline the Mayo HeartShare Research Skills Development Program. Providing HFpEF clinical investigators a short-term intensive immersion experience by collaboration with a data scientist intern in the Mayo Cardiovascular Disease AI Internship or a long term dedicated program in data science as a Mayo Kern Center Scholar in Data Science will equip a new generation of HFpEF investigators with a robust data science toolbox to drive future discovery.
项目总结/摘要 这是马约诊所作为HeartShare参与NIH HeartShare研究联盟的申请 临床中心(CC)。我们的目标是与其他HeartShare研究人员合作, 射血分数保留性心力衰竭(HF)的病理生理学,并发现新的诊断方法 和治疗方法。多种病理生理过程可能最终导致不同的HFpEF 表型,但具体机制仍在很大程度上不明确。也不知道标准是否 临床信息可以识别具有不同机械病因的患者,这对于提供 靶向治疗在临床试验中,并最终在临床实践中。我们的提案概述了四个具体目标。在 具体目标1:我们记录了马约诊所拥有资源,马约心连心团队拥有 在HFpEF和相关疾病、临床研究、患者 招聘和保留,数据科学和协作团队科学,以帮助推动成功 HeartShare Network.在具体目标2:我们提出了一个广泛的机制表型方案, 反映衰老、全身性疾病过程和多器官完整性的定量变量(L2 数据),它们被用作无监督机器学习(ML)模型的输入变量。我们假设 该方法将允许鉴定独特的HFpEF病理生理表型组(簇)。我们也 提出侵入性血流动力学特征,循环生物标志物和心肌的跨心脏梯度, 在每个HFpEF内的子集中获得脂肪和骨骼肌组织表征(L3数据) 病理生理表型群我们假设这些L3数据将增强靶向治疗药物的识别, 战略布局最后,我们使用EHR数据概述了监督ML,以开发可自动化的算法, 鉴定使用L2数据导出的HeartShare HFpEF病理生理表型组。我们假设如果 如果成功,这种方法将通过允许自动识别来增强HeartShare发现的翻译 不同HFpEF表型组中的患者招募入靶向其特异性的药物的临床试验, 病理生理学在具体目标3中:我们提出单独使用循环蛋白(n=5000;由 基于SOMAScanTM适体的平台)作为无监督ML模型的输入变量将识别独特的 HFpEF病理生理表型(簇)。在具体目标4中:我们概述了马约心分享研究 技能发展方案。为HFpEF临床研究者提供短期的强化沉浸 通过与马约心血管疾病AI实习的数据科学家实习生合作获得经验,或 一个长期的数据科学专门计划,作为马约克恩中心学者在数据科学将装备一个 新一代HFpEF研究人员拥有强大的数据科学工具箱,以推动未来的发现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barry A. Borlaug其他文献

HEMODYNAMIC RESPONSES TO ARTERIAL VASODILATION FUNDAMENTALLY DIFFER IN HEART FAILURE WITH PRESERVED VERSUS REDUCED EJECTION FRACTION
  • DOI:
    10.1016/s0735-1097(11)60196-4
  • 发表时间:
    2011-04-05
  • 期刊:
  • 影响因子:
  • 作者:
    Shmuel Schwartzenberg;Margaret M. Redfield;Aaron M. From;Sorajja Paul;Rick A. Nishimura;Barry A. Borlaug
  • 通讯作者:
    Barry A. Borlaug
The pathophysiology of heart failure with preserved ejection fraction
射血分数保留的心力衰竭的病理生理学
  • DOI:
    10.1038/nrcardio.2014.83
  • 发表时间:
    2014-06-24
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Barry A. Borlaug
  • 通讯作者:
    Barry A. Borlaug
Impact of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
  • DOI:
    10.1016/j.cardfail.2018.07.018
  • 发表时间:
    2018-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Katlyn E. Koepp;Masaru Obokata;Yogesh N. Reddy;Thomas P. Olson;Barry A. Borlaug
  • 通讯作者:
    Barry A. Borlaug
Heart Failure With Preserved Ejection Fraction: emJACC/em Scientific Statement
射血分数保留的心力衰竭:emJACC/em 科学声明
  • DOI:
    10.1016/j.jacc.2023.01.049
  • 发表时间:
    2023-05-09
  • 期刊:
  • 影响因子:
    22.300
  • 作者:
    Barry A. Borlaug;Kavita Sharma;Sanjiv J. Shah;Jennifer E. Ho
  • 通讯作者:
    Jennifer E. Ho
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program
心房颤动与司美格鲁肽在射血分数保留的肥胖相关性心力衰竭中的作用:STEP-HFpEF项目
  • DOI:
    10.1016/j.jacc.2024.08.023
  • 发表时间:
    2024-10-22
  • 期刊:
  • 影响因子:
    22.300
  • 作者:
    Subodh Verma;Javed Butler;Barry A. Borlaug;Melanie J. Davies;Dalane W. Kitzman;Mark C. Petrie;Sanjiv J. Shah;Thomas Jon Jensen;Søren Rasmussen;Cecilia Rönnbäck;Bela Merkely;Evan O’Keefe;Mikhail N. Kosiborod;STEP-HFpEF and STEP-HFpEF DM Investigators
  • 通讯作者:
    STEP-HFpEF and STEP-HFpEF DM Investigators

Barry A. Borlaug的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barry A. Borlaug', 18)}}的其他基金

Pulmonary Hypertension in Left Heart Disease
左心病肺动脉高压
  • 批准号:
    10656879
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
Mayo Clinic HeartShare Clinical Center
梅奥诊所 HeartShare 临床中心
  • 批准号:
    10323121
  • 财政年份:
    2021
  • 资助金额:
    $ 28.1万
  • 项目类别:
Mayo Clinic HeartShare Clinical Center
梅奥诊所 HeartShare 临床中心
  • 批准号:
    10483137
  • 财政年份:
    2021
  • 资助金额:
    $ 28.1万
  • 项目类别:
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection Fraction
HL-无机亚硝酸盐可增强心力衰竭运动训练的益处并保留射血分数
  • 批准号:
    9252549
  • 财政年份:
    2016
  • 资助金额:
    $ 28.1万
  • 项目类别:
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection Fraction
HL-无机亚硝酸盐可增强心力衰竭运动训练的益处并保留射血分数
  • 批准号:
    9459406
  • 财政年份:
    2016
  • 资助金额:
    $ 28.1万
  • 项目类别:

相似海外基金

Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
  • 批准号:
    MR/Y013891/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
  • 批准号:
    BB/Y006542/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Research Grant
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
  • 批准号:
    479570
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
  • 批准号:
    488898
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Operating Grants
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
  • 批准号:
    23H03323
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
  • 批准号:
    23K08293
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
  • 批准号:
    23K19922
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Adipose Tissue T Cell Polarization and Metabolic Health in Persons Living with HIV
HIV 感染者的脂肪组织 T 细胞极化和代谢健康
  • 批准号:
    10619176
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
  • 批准号:
    10604611
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了